Neuroscience at Umeå University (UmU) and the University Hospital of Northern Sweden (NUS) have brought together internationally leading research groups that are part of national strategic research programmes.

This includes neurodevelopment, basic mechanisms supporting motor and cognitive functions and the molecular biology of neurodegenerative disorders. Key infrastructure resources include world-leading brain imaging platforms and biobanks.

Professor Peter Andersen is a prominent neuroscience researcher and senior clinical neurologist focusing on the fatal neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). For an example of neuroscience research at Umeå University, read more about his research here.

Professor Peter Andersen
Image Mattias Pettersson

Research within neuroscience is conducted at the following departments

Department of Medical Biochemistry and Biophysics
Department of Molecular Biology
Umeå Centre for Molecular Medicine
Umeå Centre for Functional Brain Imaging
Department of Biobank Research
Department of Pharmacology and Clinical Neuroscience
Department of Radiation Sciences
Department of Integrative Medical Biology
Department of Medical Biosciences

Looking to slow down ALS in its early tracks

Professor Peter Andersen is a prominent neuroscience researcher at Umeå University and senior clinical neurologist at the University Hospital of Umeå. Andersen’s research group performs pre-clinical and clinical studies on the fatal neurodegenerative diseases Amyotrophic lateral sclerosis (ALS) and Frontotemporal dementia (FTD), two diseases now considered to be the same process in different parts of the brain.

His group has identified a number of genes linked to ALS and FTD. It has also discovered that in autopsied patients, proteins, in particular SOD1, accumulate in neurons forming aggregates. The group has purified such aggregates and is performing experimental studies to investigate the development of the diseases. By studying blood samples from healthy people carrying the gene mutations, the group is also searching for early biomarkers of ALS and FTD, before the symptoms appear.

“In the coming years, we aim together with the pharmaceutical industry to test a number of medications in humans that can potentially inhibit SOD1 and the hereditary triggers for ALS-FTD,” says Andersen.